Skip to content

Author

A. Singh

We have 6 of 31 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Lipid-based Nanocarriers for Neurodegenerative Disorders: Bridging Blood-brain Barrier Biology and Translational Drug Delivery.

INTRODUCTION Neurodegenerative disorders, including Alzheimer's, Parkinson's, Huntington's disease, and amyotrophic lateral sclerosis, remain difficult to treat because the Blood-brain Barrier (BBB) severely restricts therapeutic access to the central nervous system. This review evaluates BBB biology and the potential...

A. Singh, Shatrudhan Prajapati, Shikha Yadav et al. · 0 citations
Review Sep 2026

Integrating AI Technologies and Drug Therapies in the Fight against Dementia: A Review

Dementia is a progressive, neurodegenerative disease that involves a gradual loss of functions of the brain, such as memory, reasoning, and attention. This review will assess the association between Artificial Intelligence (AI) technologies and the pharmacological treatment of dementia for diagnosis and treatment....

Namrata Bhadauria, A. Singh, Niranjan Kaushik et al. · 0 citations
Review Sep 2026

siRNA and mRNA Therapeutics: A Comprehensive Review of Mechanisms, Delivery Strategies, Clinical Applications, and Future Directions in Precision Pharmacology.

Small interfering RNA (siRNA) and messenger RNA (mRNA) therapeutics represent transformative approaches in precision pharmacology, enabling targeted gene silencing and protein expression, respectively. This review provides a comprehensive analysis of their molecular mechanisms, delivery strategies, clinical application...

Ritu Dahiya, A. Singh, Pooja Mathur et al. · 0 citations
Review Aug 2026

FAK and PYK2 as Central Resistance Nodes in Non-Small Cell Lung Cancer: Signalling Crosstalk and Combination Therapeutic Strategies

Non-Small Cell Lung Cancer (NSCLC) remains a major clinical challenge and is one of the leading causes of cancer-related mortality worldwide. Its poor prognosis is driven by substantial molecular heterogeneity, dynamic interactions between tumor cells and the surrounding microenvironment, and the frequent developme...

Shatrudhan Prajapati, Shabana Khatoon, A. Singh et al. · 0 citations
Review Jul 2026

Integrative Phytotherapy for Neurodegenerative Disorders: Bridging Traditional Botanicals, Bioactive Compounds, and Nanotechnology.

Neurodegenerative disorders (NDDs) such as Alzheimer's, Parkinsons etc., are progressive and debilitating conditions that have little therapeutic intervention. Existing pharmacological interventions mainly provide symptomatic relief and do not respond to the pathophysiology of these diseases, which is complex and multi...

Shatrudhan Prajapati, Shikha Yadav, A. Singh et al. · 0 citations
Review Aug 2026

Reprogramming the Breast Cancer Immune Microenvironment Using Nanoparticle-based Therapeutic Platforms

Breast cancer is also one of the most common causes of cancerrelated deaths in the world, and this is mainly because of the therapeutic resistance and immune evasion mechanisms in the tumor microenvironment. An immunosuppressive tumor microenvironment, characterized by dysfunctional immune cells and stromal impedim...

A. Singh, Shatrudhan Prajapati, Shikha Yadav et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.